ES2869309T3 - Método para la conjugación de proteínas con tioéter - Google Patents

Método para la conjugación de proteínas con tioéter Download PDF

Info

Publication number
ES2869309T3
ES2869309T3 ES14818938T ES14818938T ES2869309T3 ES 2869309 T3 ES2869309 T3 ES 2869309T3 ES 14818938 T ES14818938 T ES 14818938T ES 14818938 T ES14818938 T ES 14818938T ES 2869309 T3 ES2869309 T3 ES 2869309T3
Authority
ES
Spain
Prior art keywords
protein
conjugation
reduction
solution
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14818938T
Other languages
English (en)
Spanish (es)
Inventor
Charlotte Schou Hunneche
Thomas Budde Hansen
Ernst Broberg Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of ES2869309T3 publication Critical patent/ES2869309T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14818938T 2013-12-13 2014-12-15 Método para la conjugación de proteínas con tioéter Active ES2869309T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197150 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (1)

Publication Number Publication Date
ES2869309T3 true ES2869309T3 (es) 2021-10-25

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14818938T Active ES2869309T3 (es) 2013-12-13 2014-12-15 Método para la conjugación de proteínas con tioéter

Country Status (6)

Country Link
US (1) US11219690B2 (cg-RX-API-DMAC7.html)
EP (1) EP3079722B1 (cg-RX-API-DMAC7.html)
JP (1) JP6603662B2 (cg-RX-API-DMAC7.html)
CN (1) CN106068127B (cg-RX-API-DMAC7.html)
ES (1) ES2869309T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015086853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
KR20200019122A (ko) 2017-06-20 2020-02-21 암젠 인크 Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
CA3066251A1 (en) 2017-06-21 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
ES2997332T3 (en) * 2017-08-04 2025-02-17 Amgen Inc Method of conjugation of cys-mabs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7306931B2 (en) 2000-05-16 2007-12-11 Bolder Biotechnology, Inc. Method for refolding proteins containing free cysteine residues
KR100731826B1 (ko) 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
WO2007109475A2 (en) * 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
US8586532B2 (en) 2007-08-24 2013-11-19 Novo Nordisk Healthcare A/G Method for selectively modifying a protein via transglutaminase catalyzed reaction
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
EP3808378A1 (en) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
CN107163101B (zh) * 2011-11-02 2021-08-17 弗·哈夫曼-拉罗切有限公司 超载和洗脱层析
CN103087183A (zh) 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Also Published As

Publication number Publication date
US11219690B2 (en) 2022-01-11
EP3079722B1 (en) 2021-03-24
WO2015086853A1 (en) 2015-06-18
JP6603662B2 (ja) 2019-11-06
JP2017501148A (ja) 2017-01-12
US20160303248A1 (en) 2016-10-20
CN106068127B (zh) 2020-06-19
EP3079722A1 (en) 2016-10-19
CN106068127A (zh) 2016-11-02

Similar Documents

Publication Publication Date Title
ES2869309T3 (es) Método para la conjugación de proteínas con tioéter
PT2100904E (pt) Fase sólida para utilização num método para a purificação de conjugados de albumina
Brocchini et al. Disulfide bridge based PEGylation of proteins
ES2959257T3 (es) Composición farmacéutica que comprende construcciones de anticuerpo biespecífico
ES2197373T3 (es) Fragmentos de anticuerpos monovalentes.
JP6023703B2 (ja) 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
Zhang et al. Chromatographic separation of hemoglobin variants using robust molecularly imprinted polymers
Kragh-Hansen Human serum albumin: a multifunctional protein
ES2897935T3 (es) Método para mejorar la solubilidad de proteína y péptido mediante el uso del enlace a un fragmento Fc de inmunoglobulina
NZ254661A (en) Polyethylene oxide/haemoglobin conjugates, fractionation thereof with anion exchangers
WO2013142135A1 (en) Method of enhancing efficacy of blood transfusions
BR112013024706B1 (pt) Método para preparar análogos de exendina peguilada e análogo de exendina peguilada
JP4406169B2 (ja) ヘモグロビン−ハプトグロビン複合体
RU2015135518A (ru) Гликомодифицированный предсердный натрийуретический пептид
US11053278B2 (en) Tangential flow filtration based protein refolding methods
CN107108717B (zh) 一种可溶且稳定的异质二聚tcr
Savla et al. Structural stability and biophysical properties of the mega-protein erythrocruorin are regulated by polyethylene glycol surface coverage
EP1301075A1 (en) Modified serum albumin with reduced affinity for nickel and copper
Zhang et al. Site-selective glycosylation of hemoglobin on Cys β93
JP2017501148A5 (cg-RX-API-DMAC7.html)
BR112015021764B1 (pt) Método de preparação melhorado para a produção com alto rendimento de conjugado de polipeptídeo fisiologicamente ativo
ITMI20071119A1 (it) Nuovi ligandi sintetici per immunoglobuline e composizioni farmaceutiche che li comprendono
JP5713006B2 (ja) チオスルホナート化合物、タンパク質及び／又はペプチドの可逆的カチオン化剤並びに可溶化方法
CN106459176B (zh) 高亲和力hcv t细胞受体
Huey Development of a monodisperse oligomeric hemoglobin-based oxygen carrier for acute blood replacement therapy